MANIFESTO

We are singularly focused on defeating diseases of muscle and metabolism in our lifetimes through rigorous therapeutic discovery and development. Our mission is to make genetics less of a barrier and more of an opportunity.

OUR TEAM
Xander Dunn

Xander Dunn

FOUNDER & CEO

VP of Engineering, Numerai. Built a team and took a machine learning hedge fund from idea to market, creating hundreds of millions dollars in value.

Machine learning engineer at Osaro.

Engineer at Apple.

Xander Dunn

VP of Engineering, Numerai. Built a team and took a machine learning hedge fund from idea to market, creating hundreds of millions dollars in value.

Machine learning engineer at Osaro.

Engineer at Apple.

Dr. Tom Thompson

Dr. Tom Thompson

SCIENTIFIC FOUNDER

Dr. Tom Thompson

Dr. Tom Thompson’s laboratory is divided into two areas of investigation where he studies the structural and functional aspects of TGFbeta family signaling and regulation along with the structures of apolipoproteins and how this relates to HDL particles and other related biological functions. The laboratory uses a combination of structural techniques including X-ray crstallography, small angle X-ray scattering coupled with biophysical and biochemical experiments.

Anukana

Anukana

COFOUNDER & PRINCIPAL SCIENTIST

Anukana

Postdoctoral Training, Neurological Surgery, UCSF

Anukana’s research focused on developing a novel brain organogenesis model for medulloblastoma group 4 patients and a next generation sequencing based approach to understand brain mosaicism. She has expertise in investigating the mechanism underlying telomere length regulation in cancer cells.

She worked as project manager and volunteer consultant under BCBA for Mammoth Diagnostics and sRNAlytics and holds a Ph.D. in Molecular Genetics and Biochemistry from the University of Cincinnati.

Lee Sweeney

Lee Sweeney

SCIENTIFIC ADVISOR

Lee Sweeney

H. Lee Sweeney, Ph.D., is currently Director of the Myology Institute at the University of Florida College of Medicine. Prior to this, he was William Maul Measey Professor and Chairman of the Department of Physiology at the University of Pennsylvania School of Medicine. Dr. Sweeney’s research interests include molecular motors, muscle injury and disease, gene transfer into striated muscle, myofibrillogenesis. Much of his research program is translational in focus, and has produced highly cited research on inherited forms of cardiovascular disease, and on the skeletal and cardiac aspects of muscular dystrophy. Dr. Sweeney is well known in the popular press for his gene-therapy approaches to permanently block the loss of age-related muscle size and strength in mice. The technique suggests that therapies for humans could reverse the feebleness associated with old age or slow the muscle-wasting effects of muscular dystrophies.

Se-Jin Lee

Se-Jin Lee

SCIENTIFIC ADVISOR

Se-Jin Lee

Dr. Se-Jin Lee received a degree in biochemistry from Harvard University and completed both his M.D. and Ph.D. in molecular biology and genetics at Johns Hopkins, and joined its faculty in 1991. Dr. Lee’s breakthrough research includes discovering myostatin (GDF8), a protein that blocks muscle growth. His work has shown that lack of myostatin leads to dramatic increase in skeletal muscle mass in the body. Dr. Lee is exploiting the biological properties of myostatin and other TGF-B family proteins to develop novel therapeutic strategies for treating patients with muscle degenerative and wasting conditions, such as muscular dystrophy, sarcopenia, and cachexia. Dr. Lee holds more than 50 U.S. patents and is both a member of the National Academy of Sciences and a fellow of the American Association for the Advancement of Science. In 2013, Dr. Lee won the Ho-Am Prize in Medicine, often referred to as the Korean equivalent of the Nobel Prize.

Nick Conley

Nick Conley

ADVISOR

Nick Conley

Dr. Nick Conley is Principal Scientist for Locus Biosciences. Before joining Locus in 2018, Nick was co-founder of EpiBiome, a South San Francisco-based precision microbiome engineering company that built the world’s first fully automated high-throughput phage discovery, characterization, and genomics platform. During this time, the company gained admission into Illumina Accelerator, Johnson & Johnson Innovation’s JLABS, and Stanford-StartX; secured non-dilutive funding from the Bill & Melinda Gates Foundation and the US Department of Defense; established a top-3 pharma partnership; and raised more than $10 million dollars in financing. Prior to EpiBiome, Nick was Staff Scientist at HGST, a Western Digital Company.

Nick completed a postdoc in Developmental Biology at Stanford University, and holds a PhD and BS in Chemistry from Stanford University and The University of Texas at Austin.